- Home
- HNVR vs RCEL Comparison
HNVR vs RCEL Comparison
Compare HNVR & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- RCEL
- Stock Information
- Founded
- HNVR 2008
- RCEL N/A
- Country
- HNVR United States
- RCEL United States
- Employees
- HNVR N/A
- RCEL N/A
- Industry
- HNVR Commercial Banks
- RCEL Medical/Dental Instruments
- Sector
- HNVR Finance
- RCEL Health Care
- Exchange
- HNVR Nasdaq
- RCEL Nasdaq
- Market Cap
- HNVR 164.7M
- RCEL 161.5M
- IPO Year
- HNVR 2022
- RCEL N/A
- Fundamental
- Price
- HNVR $21.48
- RCEL $5.19
- Analyst Decision
- HNVR Buy
- RCEL Strong Buy
- Analyst Count
- HNVR 1
- RCEL 4
- Target Price
- HNVR $22.00
- RCEL $16.50
- AVG Volume (30 Days)
- HNVR 11.9K
- RCEL 293.0K
- Earning Date
- HNVR 07-23-2025
- RCEL 08-07-2025
- Dividend Yield
- HNVR 1.84%
- RCEL N/A
- EPS Growth
- HNVR N/A
- RCEL N/A
- EPS
- HNVR 1.31
- RCEL N/A
- Revenue
- HNVR $65,041,000.00
- RCEL $71,661,000.00
- Revenue This Year
- HNVR N/A
- RCEL $57.29
- Revenue Next Year
- HNVR $13.69
- RCEL $28.07
- P/E Ratio
- HNVR $16.40
- RCEL N/A
- Revenue Growth
- HNVR 5.06
- RCEL 41.35
- 52 Week Low
- HNVR $15.92
- RCEL $5.10
- 52 Week High
- HNVR $27.14
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- HNVR 42.03
- RCEL 29.07
- Support Level
- HNVR $20.79
- RCEL $5.10
- Resistance Level
- HNVR $21.93
- RCEL $6.33
- Average True Range (ATR)
- HNVR 0.50
- RCEL 0.32
- MACD
- HNVR -0.11
- RCEL 0.02
- Stochastic Oscillator
- HNVR 36.22
- RCEL 6.10
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.